Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (11863)	6/2/2004 9:48:57 AM
From: charlyt	Read Replies (1) \| Respond to of 52153

That PR seems a bit misleading. Kind of makes it seem like the drug got approved when what the FDA said was if your current trial shows efficacy then we'll approve it. A big difference. At least that's my read of this PR: biz.yahoo.com <<"We are pleased that the FDA has determined that RSR13 is approvable, assuming a favorable outcome of our ENRICH study," said Michael Hart, President and Chief Executive Officer of Allos. "We remain focused on completing the enrollment of the ENRICH study as soon as possible, and will continue to work with the FDA with the goal of advancing RSR13 toward approval.>>